---
title: Opportunities to Improve Drug Price Transparency at the Point of Prescribing
description: A new revolution is coming to the point of care. It leverages electronic prescribing to provide accuratemedication prices at the point of prescribing.
image: https://blog.pocp.com/hubfs/Imported_Blog_Media/pa-web.jpg
---
[](https://www.pocp.com/)
# Accelerating client's success
# using Health IT and
# business process solutions...
[Learn More](https://www.pocp.com/the-pocp-story/)
# Simplifying
# regulatory
## compliance...
[Learn More](https://www.pocp.com/regulatory-resource-center/)
# Creating value in today's
# healthcare ecosystem...
[Learn More](https://www.pocp.com/our-client/)
- Consulting
- [Strategy & Market Intelligence](https://www.pocp.com/strategy-market-intelligence/)
- [Education & Research](https://www.pocp.com/education-research/)
- [Value-Based Care Interoperability Roadmap](https://info.pocp.com/en-us/value-based-care-interoperability-strategy-and-roadmap)
- [Multi-stakeholder Collaboratives, Program Design and Management](https://www.pocp.com/multi-stakeholder-initiatives_program-design_management)
- [EHR Training Programs](https://www.pocp.com/ehr-training-programs/)
- [Life Sciences](https://www.pocp.com/life-sciences)
- [Regulatory Resource Center](https://www.pocp.com/regulatory-resource-center)
- About Us
- [The POCP Story](https://www.pocp.com/the-pocp-story/)
- [Our Clients](https://www.pocp.com/our-client/)
- [Health & IT Vendors](https://www.pocp.com/our-client/health-it-vendors/)
- [Payers & PBMS](https://www.pocp.com/our-client/payers-pbms/)
- [Accountable Care](https://www.pocp.com/our-client/accountable-care/)
- [Health Information Exchange](https://www.pocp.com/resource-library/health-information-exchange/)
- [Our Team](https://www.pocp.com/our-team/)
- [Government Contracting](https://info.pocp.com/gsa)
- [Press](https://www.pocp.com/press/)
- [Calendar](https://info.pocp.com/en-us/events)
- [Careers at POCP](https://www.pocp.com/the-pocp-story/careers-at-pocp/)
- Insights
- [Articles and Industry Comments](https://www.pocp.com/articles/)
- [Blog](https://blog.pocp.com/blog/)
- [Newsletters HIT Perspectives](https://www.pocp.com/insight/newsletters-2/)
- [Newsletters Biopharma](https://www.pocp.com/newsletters-biopharma/)
- [POCP Industry Reports](https://www.pocp.com/industry-reports)
- [POCP Industry Reports](https://www.pocp.com/industry-reports)
- [ePrior Authorization’s Real Benefits: Reducing Frictional Costs and Speeding Time to Therapy](https://www.pocp.com/downloads/ePAReport)
- [Real-Time Pharmacy Benefit Check Report](https://www.pocp.com/pocp-industry-reports/real-time-pharmacy-benefit-check-report/)
- [Fighting the Opioid Epidemic at the State- and Rx-Level Report](https://www.pocp.com/downloads/fighting-opioid-epidemic-at-rx-level-report)
- [ePrescribing State Law On-Demand](https://www.pocp.com/downloads/eprescribing-state-law-on-demand/)
- [State Law Review](https://www.pocp.com/statelawreview/)
- [Navigator](https://www.pocp.com/navigator/)
- [Podcasts](https://info.pocp.com/en-us/the-dish-on-health-it-podcast)
- [Presentations and Webinars](https://www.pocp.com/presentations/)
- [Resource Library](https://www.pocp.com/resource-library/)
- [White Papers, Webinars and Case Studies](https://www.pocp.com/white-papers-webinars-and-case-studies-2/)
- [Our video channel](https://www.pocp.com/our-video-channel)
- [Contact](https://www.pocp.com/contact/)
- Consulting
- [Strategy & Market Intelligence](https://www.pocp.com/strategy-market-intelligence/)
- [Education & Research](https://www.pocp.com/education-research/)
- [Value-Based Care Interoperability Roadmap](https://info.pocp.com/en-us/value-based-care-interoperability-strategy-and-roadmap)
- [Multi-stakeholder Collaboratives, Program Design and Management](https://www.pocp.com/multi-stakeholder-initiatives_program-design_management)
- [EHR Training Programs](https://www.pocp.com/ehr-training-programs/)
- [Life Sciences](https://www.pocp.com/life-sciences)
- [Regulatory Resource Center](https://www.pocp.com/regulatory-resource-center)
- About Us
- [The POCP Story](https://www.pocp.com/the-pocp-story/)
- [Our Clients](https://www.pocp.com/our-client/)
- [Health & IT Vendors](https://www.pocp.com/our-client/health-it-vendors/)
- [Payers & PBMS](https://www.pocp.com/our-client/payers-pbms/)
- [Accountable Care](https://www.pocp.com/our-client/accountable-care/)
- [Health Information Exchange](https://www.pocp.com/resource-library/health-information-exchange/)
- [Our Team](https://www.pocp.com/our-team/)
- [Government Contracting](https://info.pocp.com/gsa)
- [Press](https://www.pocp.com/press/)
- [Calendar](https://info.pocp.com/en-us/events)
- [Careers at POCP](https://www.pocp.com/the-pocp-story/careers-at-pocp/)
- Insights
- [Articles and Industry Comments](https://www.pocp.com/articles/)
- [Blog](https://blog.pocp.com/blog/)
- [Newsletters HIT Perspectives](https://www.pocp.com/insight/newsletters-2/)
- [Newsletters Biopharma](https://www.pocp.com/newsletters-biopharma/)
- [POCP Industry Reports](https://www.pocp.com/industry-reports)
- [POCP Industry Reports](https://www.pocp.com/industry-reports)
- [ePrior Authorization’s Real Benefits: Reducing Frictional Costs and Speeding Time to Therapy](https://www.pocp.com/downloads/ePAReport)
- [Real-Time Pharmacy Benefit Check Report](https://www.pocp.com/pocp-industry-reports/real-time-pharmacy-benefit-check-report/)
- [Fighting the Opioid Epidemic at the State- and Rx-Level Report](https://www.pocp.com/downloads/fighting-opioid-epidemic-at-rx-level-report)
- [ePrescribing State Law On-Demand](https://www.pocp.com/downloads/eprescribing-state-law-on-demand/)
- [State Law Review](https://www.pocp.com/statelawreview/)
- [Navigator](https://www.pocp.com/navigator/)
- [Podcasts](https://info.pocp.com/en-us/the-dish-on-health-it-podcast)
- [Presentations and Webinars](https://www.pocp.com/presentations/)
- [Resource Library](https://www.pocp.com/resource-library/)
- [White Papers, Webinars and Case Studies](https://www.pocp.com/white-papers-webinars-and-case-studies-2/)
- [Our video channel](https://www.pocp.com/our-video-channel)
- [Contact](https://www.pocp.com/contact/)
# Insights: Brief Points of View
# POCP Blog
---
## Opportunities to Improve Drug Price Transparency at the Point of Prescribing
- October 04, 2018
- By [Tony Schueth](https://blog.pocp.com/blog/author/tony-schueth)
- [0 Comment](https://blog.pocp.com/blog/drug-price-transparency-blog#comments-listing)
Share this story:
By [**Tony Schueth**](https://www.pocp.com/team/anthony-j-tony-schueth-ms/), CEO and Managing Partner
A new revolution is coming to the point of care. It leverages electronic prescribing (ePrescribing) to provide accurate, patient-specific information on medication prices and related out-of-pocket (OOP) costs at the point of prescribing. As described in our [last blog](https://www.pocp.com/drug-transparency-drivers) on this topic, such actionable information will help reduce costs, improve medication adherence and outcomes and enhance patient and provider satisfaction. This blog describes recent advances and six opportunities for improvement.
1. **Developing RTBC for drugs covered under the medical benefit.** The current Real-Time Benefit Check (RTBC) transaction focuses on medications covered under the pharmacy benefit. Yet a similar transaction is needed for specialty drugs covered under the medical benefit. The use of specialty medications is rapidly growing and roughly half are covered under the medical benefit. Use of RTBC could help identify the benefit the drug is covered under and address long-standing issues of transparency and access. It could also help providers understand benefit restrictions, find less expensive alternatives and identify the appropriate specialty pharmacy to fill the prescription. This will help lower costs and improve speed to therapy, outcomes and patient satisfaction while reducing hassles for the prescriber. However, RTBC for medical benefit drugs is on a longer-term horizon because specialty pharmacy is in the very early days of automation.
1. **Improving formulary and benefit (F&B) files.** The need for F&B files will not go away with the advent of RTBC. Rather, F&B will evolve to support RTBC by consistently alerting prescribers of the need to perform a RTBC due to such mitigating factors as noncovered drugs. Thus, eligibility-informed formulary is still important because it helps determine whether an RTBC is needed. As a result, payers must address the shortcomings in F&B data. For example, they must improve the completeness and accuracy of data regarding individual patients’ insurance coverage, coverage restrictions, therapeutic class guidelines, and deductibles. The need for prior authorization will migrate to the RTBC response transaction, where it can more accurately reflect member-specific benefits.
1. **Fixing the prescription rework challenge.** ePrescribing vendors need to be innovative to address a challenge related to prescription rework when using the RTBC. Prescribers using the RTBC frequently change the drug prescribed when provided with information regarding a patient’s insurance coverage and OOP costs. When that happens, the prescriber is faced with extra steps when selecting an alternative--whether it’s for an entirely different medication or just a change in packaging and strength. This one reason is why so many prescribers let the pharmacist sort it out by phone, which may be handled by a nurse, instead of rewriting the prescription. Such rework takes time away from the patient visit and adds to physician dissatisfaction. Interoperability between the EHR system’s ePrescribing system and RTBC application must be carefully designed and implemented to pass RTBC results as a new prescription to eliminate clinician rework.
1. **Settling on a pricing model.** Because of the way RTBC has evolved, there are varying pricing models for use of the transaction. Pricing may be outcomes based for those payers engaging in significant numbers of value-based contracts. Our research shows multiple pricing models will likely be in place for quite some time and the reimbursement models will support quality measures. These include getting patients on the appropriate, on-formulary drug; avoiding drugs requiring prior authorization when an alternative is available; and improving medication adherence.
1. **Integrating information on payment assistance programs.** Another information gap is the unavailability of information on payment assistance programs offered by manufacturers and others. Having this information at the point of prescribing can help the physician identify more cost-effective options, which ultimately improves outcomes and medication adherence and reduces costs. Assistance is available from various sources. Many manufacturers fund coupon and copay card programs to offset the costs of drugs for consumers. They also fund financial assistance for patients’ drug copays or other medical expenses through nonprofit foundations. Many [states](http://www.ncsl.org/research/health/state-pharmaceutical-assistance-programs.aspx) have similar programs. Several payers also offer drug assistance programs, such as [CVS Health](https://payorsolutions.cvshealth.com/insights/consumer-transparency) and Express Scripts’ [InsideRx](https://www.prnewswire.com/news-releases/inside-rx-a-prescription-savings-program-from-express-scripts-expands-list-of-discounted-brand-name-medications-300641894.html).
Such information can be incorporated into the ePrescribing workflow so it is available at the point of prescribing. While this is an opportunity, there are challenges for EHR vendors. They must identify assistance programs, figure out how to integrate the information into their EHR and keep the information updated.
1. **Understanding the patient’s financial picture.** The prescriber is likely to lack information concerning a drug’s affordability. Factors include coinsurance, other insurance copayments, and drug deductibles, as well as the patient’s finances. The RTBC only provides a snapshot of a patient’s potential OOP cost for a particular drug at a particular time. This varies because payers do not calculate the patient’s OOP costs the same way and there is no standard for presenting OOP costs. In addition, the RTBC may not aggregate OOP costs for all drugs prescribed for an individual patient, so the problem is exacerbated when multiple drugs are prescribed at the same time. Other unknown financial factors may affect medication affordability, including income and personal responsibilities.
All of this is unknown to the provider at the point of care, who may have to ask about such very personal information — especially if the patient needs a very expensive drug with a very large copay, such as an oncology medication. Providers may be reluctant to have this discussion and patients likewise may be reluctant to provide such information and keep it available in the EHR.
These kinds of sensitive financial issues must be addressed going forward if drug price transparency at the point of care is to become an optimal tool for providers and consumers.
**Moving forward.** Considerable headway has been made to streamline processes, reduce costs and improve speed to therapy through advancements in drug price transparency at the point of prescribing. The RTBC will become a valuable tool to help ensure that patients will get the right, most cost-effective approved drug before they get to the pharmacy.
Keep current with Point-of-Care Partners. We are monitoring these developments and are active in the development of — and enhancements to – these and other standards related to ePrescribing. Drop me an email at [tonys@pocp.com](mailto:tonys@pocp.com). I’d be happy to fill you in.
- Post Categories
- [Drug price transparency](https://blog.pocp.com/blog/tag/drug-price-transparency)
- [Real-Time Benefit Check](https://blog.pocp.com/blog/tag/real-time-benefit-check)
# POCP Blog
---
Search
- There are no suggestions because the search field is empty.
### RECENT POSTS
### CATEGORIES
- [Interoperability (39)](https://blog.pocp.com/blog/tag/interoperability)
- [Health IT Policy (38)](https://blog.pocp.com/blog/tag/health-it-policy)
- [CMS (28)](https://blog.pocp.com/blog/tag/cms)
- [EHR (24)](https://blog.pocp.com/blog/tag/ehr)
- [FHIR (24)](https://blog.pocp.com/blog/tag/fhir)
- [Health IT Trends (20)](https://blog.pocp.com/blog/tag/health-it-trends)
- [ePrescribing (19)](https://blog.pocp.com/blog/tag/eprescribing)
- [Prior Authorization (16)](https://blog.pocp.com/blog/tag/prior-authorization)
- [Real-Time Benefit Check (15)](https://blog.pocp.com/blog/tag/real-time-benefit-check)
- [Real-Time Pharmacy Benefit Check (15)](https://blog.pocp.com/blog/tag/real-time-pharmacy-benefit-check)
- [Regulatory Trends (15)](https://blog.pocp.com/blog/tag/regulatory-trends)
- [APIs (13)](https://blog.pocp.com/blog/tag/apis)
- [Artificial Intelligence (12)](https://blog.pocp.com/blog/tag/artificial-intelligence)
- [electronic prior authorization (12)](https://blog.pocp.com/blog/tag/electronic-prior-authorization)
- [health IT (12)](https://blog.pocp.com/blog/tag/health-it)
- [Life Sciences (10)](https://blog.pocp.com/blog/tag/life-sciences)
- [NCPDP (10)](https://blog.pocp.com/blog/tag/ncpdp)
- [Policy (10)](https://blog.pocp.com/blog/tag/policy)
- [electronic health records (9)](https://blog.pocp.com/blog/tag/electronic-health-records)
- [pharmacy interoperability (9)](https://blog.pocp.com/blog/tag/pharmacy-interoperability)
- [ASTP (8)](https://blog.pocp.com/blog/tag/astp)
- [CMS NPRM (8)](https://blog.pocp.com/blog/tag/cms-nprm)
- [health information exchange (8)](https://blog.pocp.com/blog/tag/health-information-exchange)
- [HL7 (7)](https://blog.pocp.com/blog/tag/hl7)
- [Payer (7)](https://blog.pocp.com/blog/tag/payer)
- [Specialty Pharmacy (7)](https://blog.pocp.com/blog/tag/specialty-pharmacy)
- [Standards Development (7)](https://blog.pocp.com/blog/tag/standards-development)
- [TEFCA (7)](https://blog.pocp.com/blog/tag/tefca)
- [Value-Based Care (7)](https://blog.pocp.com/blog/tag/value-based-care)
- [e-Prescribing (7)](https://blog.pocp.com/blog/tag/e-prescribing)
- [electronic prescribing (7)](https://blog.pocp.com/blog/tag/electronic-prescribing)
- [Da Vinci Project (6)](https://blog.pocp.com/blog/tag/da-vinci-project)
- [HTI-2 (6)](https://blog.pocp.com/blog/tag/hti-2)
- [ONC (6)](https://blog.pocp.com/blog/tag/onc)
- [Strategy and Research (6)](https://blog.pocp.com/blog/tag/strategy-and-research)
- [healthcare reform (6)](https://blog.pocp.com/blog/tag/healthcare-reform)
- [21st Century Cures Act (5)](https://blog.pocp.com/blog/tag/21st-century-cures-act)
- [Consent (5)](https://blog.pocp.com/blog/tag/consent)
- [EPCS (5)](https://blog.pocp.com/blog/tag/epcs)
- [Federal Healthcare Policy (5)](https://blog.pocp.com/blog/tag/federal-healthcare-policy)
- [HHS (5)](https://blog.pocp.com/blog/tag/hhs)
- [Information Blocking (5)](https://blog.pocp.com/blog/tag/information-blocking)
- [NCPDP SCRIPT (5)](https://blog.pocp.com/blog/tag/ncpdp-script)
- [Patient Data (5)](https://blog.pocp.com/blog/tag/patient-data)
- [Payer Interoperability (5)](https://blog.pocp.com/blog/tag/payer-interoperability)
- [Pharmacy (5)](https://blog.pocp.com/blog/tag/pharmacy)
- [health equity (5)](https://blog.pocp.com/blog/tag/health-equity)
- [pharmaceutical marketing (5)](https://blog.pocp.com/blog/tag/pharmaceutical-marketing)
- [population health (5)](https://blog.pocp.com/blog/tag/population-health)
- [Clinical Decision Support (4)](https://blog.pocp.com/blog/tag/cds)
- [Digital Health Programs (4)](https://blog.pocp.com/blog/tag/digital-health-programs)
- [Digital Therapeutics (4)](https://blog.pocp.com/blog/tag/digital-therapeutics)
- [EHR Dashboard (4)](https://blog.pocp.com/blog/tag/ehr-dashboard)
- [EHR Usability (4)](https://blog.pocp.com/blog/tag/ehr-usability)
- [HIE (4)](https://blog.pocp.com/blog/tag/hie)
- [Health Plans (4)](https://blog.pocp.com/blog/tag/health-plans)
- [Health Technology Solutions (4)](https://blog.pocp.com/blog/tag/health-technology-solutions)
- [Meaningful Use (4)](https://blog.pocp.com/blog/tag/meaningful-use)
- [PDMP (4)](https://blog.pocp.com/blog/tag/pdmp)
- [Pharmacy Benefit Management (4)](https://blog.pocp.com/blog/tag/pharmacy-benefit-management)
- [Strategic roadmap (4)](https://blog.pocp.com/blog/tag/strategic-roadmap)
- [burden reduction (4)](https://blog.pocp.com/blog/tag/burden-reduction)
- [ePrior Authorization (4)](https://blog.pocp.com/blog/tag/eprior-authorization)
- [healthcare regulations (4)](https://blog.pocp.com/blog/tag/healthcare-regulations)
- [pharmacy advance practice (4)](https://blog.pocp.com/blog/tag/pharmacy-advance-practice)
- [price transparency (4)](https://blog.pocp.com/blog/tag/price-transparency)
- [COVID-19 (3)](https://blog.pocp.com/blog/tag/covid-19)
- [Clinical Calculators (3)](https://blog.pocp.com/blog/tag/clinical-calculators)
- [Data Governance (3)](https://blog.pocp.com/blog/tag/data-governance)
- [Diabetes Care (3)](https://blog.pocp.com/blog/tag/diabetes-care)
- [Digital Health (3)](https://blog.pocp.com/blog/tag/digital-health)
- [Drug price transparency (3)](https://blog.pocp.com/blog/tag/drug-price-transparency)
- [EHR Reports (3)](https://blog.pocp.com/blog/tag/ehr-reports)
- [HIMSS (3)](https://blog.pocp.com/blog/tag/himss)
- [Healthcare AI (3)](https://blog.pocp.com/blog/tag/healthcare-ai)
- [Implementation (3)](https://blog.pocp.com/blog/tag/implementation)
- [Innovation (3)](https://blog.pocp.com/blog/tag/innovation)
- [Medication Therapy Management (3)](https://blog.pocp.com/blog/tag/mtm)
- [National Patient Identifier (3)](https://blog.pocp.com/blog/tag/national-patient-identifier)
- [Patient Safety (3)](https://blog.pocp.com/blog/tag/patient-safety)
- [Pharmacy Benefit (3)](https://blog.pocp.com/blog/tag/pharmacy-benefit)
- [Request for Information (3)](https://blog.pocp.com/blog/tag/request-for-information)
- [Speed to Therapy (3)](https://blog.pocp.com/blog/tag/speed-to-therapy)
- [state prescribing laws (3)](https://blog.pocp.com/blog/tag/state-prescribing-laws)
- [Administrative Burden (2)](https://blog.pocp.com/blog/tag/administrative-burden)
- [CDC (2)](https://blog.pocp.com/blog/tag/cdc)
- [Centers for Disease Control (2)](https://blog.pocp.com/blog/tag/centers-for-disease-control)
- [Controlled Substances (2)](https://blog.pocp.com/blog/tag/controlled-substances)
- [Data Efficiency (2)](https://blog.pocp.com/blog/tag/data-efficiency)
- [EHR Certification (2)](https://blog.pocp.com/blog/tag/ehr-certification)
- [EHR Guides (2)](https://blog.pocp.com/blog/tag/ehr-guides)
- [EHRs (2)](https://blog.pocp.com/blog/tag/ehrs)
- [Epic (2)](https://blog.pocp.com/blog/tag/epic)
- [Formulary and Benefit (2)](https://blog.pocp.com/blog/tag/formulary-and-benefit)
- [H.R. 6 (2)](https://blog.pocp.com/blog/tag/h-r-6)
- [Market Assessment (2)](https://blog.pocp.com/blog/tag/market-assessment)
- [Medical Benefit (2)](https://blog.pocp.com/blog/tag/medical-benefit)
- [Medical Pharmacy Benefit Integration (2)](https://blog.pocp.com/blog/tag/medical-pharmacy-benefit-integration)
- [Medicare Payment Reform (2)](https://blog.pocp.com/blog/tag/medicare-payment-reform)
- [Medication Adherence (2)](https://blog.pocp.com/blog/tag/medication-adherence)
- [Member Data (2)](https://blog.pocp.com/blog/tag/member-data)
- [NCPDP Telecommunications Standard Version F6 (2)](https://blog.pocp.com/blog/tag/ncpdp-telecommunications-standard-version-f6)
- [ONC Physician Burden Reduction (2)](https://blog.pocp.com/blog/tag/onc-physician-burden-reduction)
- [Opioid prescribing laws (2)](https://blog.pocp.com/blog/tag/opioid-prescribing-laws)
- [PGx (2)](https://blog.pocp.com/blog/tag/pgx)
- [Part D (2)](https://blog.pocp.com/blog/tag/part-d)
- [Patient Record Sharing (2)](https://blog.pocp.com/blog/tag/patient-record-sharing)
- [Pharmaceutical Manufacturers (2)](https://blog.pocp.com/blog/tag/pharmaceutical-manufacturers)
- [Policy monitoring (2)](https://blog.pocp.com/blog/tag/policy-monitoring)
- [Pre-approval Information Exchange (2)](https://blog.pocp.com/blog/tag/pre-approval-information-exchange)
- [Precision Medicine (2)](https://blog.pocp.com/blog/tag/precision-medicine)
- [REMS (2)](https://blog.pocp.com/blog/tag/rems)
- [Regulatory landscape (2)](https://blog.pocp.com/blog/tag/regulatory-landscape)
- [Specialty Pharmacy Automation (2)](https://blog.pocp.com/blog/tag/specialty-pharmacy-automation)
- [Specialty ePrescribing (2)](https://blog.pocp.com/blog/tag/specialty-eprescribing)
- [Speed to Medication Therapy (2)](https://blog.pocp.com/blog/tag/speed-to-medication-therapy)
- [Telehealth (2)](https://blog.pocp.com/blog/tag/telehealth)
- [Telemedicine (2)](https://blog.pocp.com/blog/tag/telemedicine)
- [care coordination (2)](https://blog.pocp.com/blog/tag/care-coordination)
- [compliance (2)](https://blog.pocp.com/blog/tag/compliance)
- [ePA (2)](https://blog.pocp.com/blog/tag/epa)
- [eRx (2)](https://blog.pocp.com/blog/tag/erx)
- [health dashboards (2)](https://blog.pocp.com/blog/tag/health-dashboards)
- [medication management (2)](https://blog.pocp.com/blog/tag/medication-management)
- [opioid abuse (2)](https://blog.pocp.com/blog/tag/opioid-abuse)
- [patient access (2)](https://blog.pocp.com/blog/tag/patient-access)
- [pharmacist (2)](https://blog.pocp.com/blog/tag/pharmacist)
- [pharmacy business model (2)](https://blog.pocp.com/blog/tag/pharmacy-business-model)
- [prior authorizations (2)](https://blog.pocp.com/blog/tag/prior-authorizations)
- [wearables (2)](https://blog.pocp.com/blog/tag/wearables)
- [ACO (1)](https://blog.pocp.com/blog/tag/aco)
- [AI Policy (1)](https://blog.pocp.com/blog/tag/ai-policy)
- [Antikickback Statutes Reform (1)](https://blog.pocp.com/blog/tag/antikickback-statutes-reform)
- [Biologics and Biosimilars Naming (1)](https://blog.pocp.com/blog/tag/biologics-and-biosimilars-naming)
- [Biosimilars (1)](https://blog.pocp.com/blog/tag/biosimilars)
- [Business Process (1)](https://blog.pocp.com/blog/tag/business-process)
- [CAQH Phase V Operating Rules (1)](https://blog.pocp.com/blog/tag/caqh-phase-v-operating-rules)
- [CARIN Alliance (1)](https://blog.pocp.com/blog/tag/carin-alliance)
- [CDS Hooks (1)](https://blog.pocp.com/blog/tag/cds-hooks)
- [CMS Attachments Rule (1)](https://blog.pocp.com/blog/tag/cms-attachments-rule)
- [CMS-0062P (1)](https://blog.pocp.com/blog/tag/cms-0062p)
- [CRD (1)](https://blog.pocp.com/blog/tag/crd)
- [Canada Biosimilars Naming (1)](https://blog.pocp.com/blog/tag/canada-biosimilars-naming)
- [Canadian ePrescribing (1)](https://blog.pocp.com/blog/tag/canadian-eprescribing)
- [Chronic Disease (1)](https://blog.pocp.com/blog/tag/chronic-disease)
- [Clinical Quality Language (CQL) (1)](https://blog.pocp.com/blog/tag/clinical-quality-language-cql)
- [CodeX (1)](https://blog.pocp.com/blog/tag/codex)
- [CoverMyMeds (1)](https://blog.pocp.com/blog/tag/covermymeds)
- [DSMO (1)](https://blog.pocp.com/blog/tag/dsmo)
- [DTR (1)](https://blog.pocp.com/blog/tag/dtr)
- [DTx (1)](https://blog.pocp.com/blog/tag/dtx)
- [Data Modernization Initiative (1)](https://blog.pocp.com/blog/tag/data-modernization-initiative)
- [Data quality (1)](https://blog.pocp.com/blog/tag/data-quality)
- [Designated Standards Maintenance Organizations (1)](https://blog.pocp.com/blog/tag/designated-standards-maintenance-organizations)
- [Digital Therapeutics Opportunities (1)](https://blog.pocp.com/blog/tag/digital-therapeutics-opportunities)
- [Digital Therapeutics Outlook (1)](https://blog.pocp.com/blog/tag/digital-therapeutics-outlook)
- [Discover Alliance (1)](https://blog.pocp.com/blog/tag/discover-alliance)
- [Drug Launch (1)](https://blog.pocp.com/blog/tag/drug-launch)
- [Drug Manufacturers (1)](https://blog.pocp.com/blog/tag/drug-manufacturers)
- [Drug PA (1)](https://blog.pocp.com/blog/tag/drug-pa)
- [Drug abuse (1)](https://blog.pocp.com/blog/tag/drug-abuse)
- [EHR Apps (1)](https://blog.pocp.com/blog/tag/ehr-apps)
- [Enforcement (1)](https://blog.pocp.com/blog/tag/enforcement)
- [FDA (1)](https://blog.pocp.com/blog/tag/fda)
- [FQHC (1)](https://blog.pocp.com/blog/tag/fqhc)
- [Federally Qualified Health Centers (1)](https://blog.pocp.com/blog/tag/federally-qualified-health-centers)
- [Fee-for-service (1)](https://blog.pocp.com/blog/tag/fee-for-service)
- [Gold-carding (1)](https://blog.pocp.com/blog/tag/gold-carding)
- [HIN (1)](https://blog.pocp.com/blog/tag/hin)
- [HIPAA (1)](https://blog.pocp.com/blog/tag/hipaa)
- [HIT Leaders (1)](https://blog.pocp.com/blog/tag/hit-leaders)
- [HTI-4 (1)](https://blog.pocp.com/blog/tag/hti-4)
- [Health and Human Services (1)](https://blog.pocp.com/blog/tag/health-and-human-services)
- [Health data (1)](https://blog.pocp.com/blog/tag/health-data)
- [Health system (1)](https://blog.pocp.com/blog/tag/health-system)
- [Healthcare artificial intelligence trends (1)](https://blog.pocp.com/blog/tag/healthcare-artificial-intelligence-trends)
- [Human Services (1)](https://blog.pocp.com/blog/tag/human-services)
- [Hypertension (1)](https://blog.pocp.com/blog/tag/hypertension)
- [I-STOP (1)](https://blog.pocp.com/blog/tag/i-stop)
- [Insurance (1)](https://blog.pocp.com/blog/tag/insurance)
- [Landscape analysis (1)](https://blog.pocp.com/blog/tag/landscape-analysis)
- [MACRA (1)](https://blog.pocp.com/blog/tag/macra)
- [MIPS (1)](https://blog.pocp.com/blog/tag/mips)
- [Market Intelligence (1)](https://blog.pocp.com/blog/tag/market-intelligence)
- [Market Research (1)](https://blog.pocp.com/blog/tag/market-research)
- [Medication Therapy Management (1)](https://blog.pocp.com/blog/tag/medication-therapy-management)
- [Modernizing Part D CMS-4180-P (1)](https://blog.pocp.com/blog/tag/modernizing-part-d-cms-4180-p)
- [NCPDP F&B (1)](https://blog.pocp.com/blog/tag/ncpdp-fb)
- [NCPDP SCRIPT 2017071 (1)](https://blog.pocp.com/blog/tag/ncpdp-script-2017071)
- [NCPDP Workgroups (1)](https://blog.pocp.com/blog/tag/ncpdp-workgroups)
- [NCQA (1)](https://blog.pocp.com/blog/tag/ncqa)
- [NPI (1)](https://blog.pocp.com/blog/tag/npi)
- [Objective Analysis (1)](https://blog.pocp.com/blog/tag/objective-analysis)
- [Outcomes (1)](https://blog.pocp.com/blog/tag/outcomes)
- [P2 FHIR Taskforce (1)](https://blog.pocp.com/blog/tag/p2-fhir-taskforce)
- [PAS (1)](https://blog.pocp.com/blog/tag/pas)
- [PBMs (1)](https://blog.pocp.com/blog/tag/pbms)
- [PIE (1)](https://blog.pocp.com/blog/tag/pie)
- [POCP News (1)](https://blog.pocp.com/blog/tag/pocp-news)
- [Pain Management (1)](https://blog.pocp.com/blog/tag/pain-management)
- [Pharmacogenomics (1)](https://blog.pocp.com/blog/tag/pharmacogenomics)
- [Population Health Management (1)](https://blog.pocp.com/blog/tag/population-health-management)
- [Prescribing Authority (1)](https://blog.pocp.com/blog/tag/prescribing-authority)
- [Prescribing signatures (1)](https://blog.pocp.com/blog/tag/prescribing-signatures)
- [Prescription Price Transparency (1)](https://blog.pocp.com/blog/tag/prescription-price-transparency)
- [Prescription affordability (1)](https://blog.pocp.com/blog/tag/prescription-affordability)
- [Prescription drug benefit (1)](https://blog.pocp.com/blog/tag/prescription-drug-benefit)
- [Prescription pricing (1)](https://blog.pocp.com/blog/tag/prescription-pricing)
- [Public Health (1)](https://blog.pocp.com/blog/tag/public-health)
- [Quality Measures (1)](https://blog.pocp.com/blog/tag/quality-measures)
- [Quality Reporting (1)](https://blog.pocp.com/blog/tag/quality-reporting)
- [RTBT (1)](https://blog.pocp.com/blog/tag/rtbt)
- [RTPB (1)](https://blog.pocp.com/blog/tag/rtpb)
- [Regulatory overhead (1)](https://blog.pocp.com/blog/tag/regulatory-overhead)
- [RelayHealth (1)](https://blog.pocp.com/blog/tag/relayhealth)
- [Rx renewal (1)](https://blog.pocp.com/blog/tag/rx-renewal)
- [RxBC (1)](https://blog.pocp.com/blog/tag/rxbc)
- [Sandbox (1)](https://blog.pocp.com/blog/tag/sandbox)
- [Social Determinants of Health (1)](https://blog.pocp.com/blog/tag/social-determinants-of-health)
- [Specialty Pharmacy Enrollment (1)](https://blog.pocp.com/blog/tag/specialty-pharmacy-enrollment)
- [Specialty medication (1)](https://blog.pocp.com/blog/tag/specialty-medication)
- [Stark Anti-Kickback Statute (1)](https://blog.pocp.com/blog/tag/stark-anti-kickback-statute)
- [Stark Law Reform (1)](https://blog.pocp.com/blog/tag/stark-law-reform)
- [State policy (1)](https://blog.pocp.com/blog/tag/state-policy)
- [Surescripts (1)](https://blog.pocp.com/blog/tag/surescripts)
- [Telecommunications (1)](https://blog.pocp.com/blog/tag/telecommunications)
- [Telehealth / Telemedicine (1)](https://blog.pocp.com/blog/tag/telehealth-telemedicine)
- [U.S. Senate Special Committee on Aging (1)](https://blog.pocp.com/blog/tag/u-s-senate-special-committee-on-aging)
- [Uncategorized (1)](https://blog.pocp.com/blog/tag/uncategorized)
- [Virtual Visits (1)](https://blog.pocp.com/blog/tag/virtual-visits)
- [Working from home (1)](https://blog.pocp.com/blog/tag/working-from-home)
- [X12 (1)](https://blog.pocp.com/blog/tag/x12)
- [blockchain (1)](https://blog.pocp.com/blog/tag/blockchain)
- [care gaps (1)](https://blog.pocp.com/blog/tag/care-gaps)
- [community pharmacy (1)](https://blog.pocp.com/blog/tag/community-pharmacy)
- [consumerism (1)](https://blog.pocp.com/blog/tag/consumerism)
- [data platforms (1)](https://blog.pocp.com/blog/tag/data-platforms)
- [digiceuticals (1)](https://blog.pocp.com/blog/tag/digiceuticals)
- [digital health platforms (1)](https://blog.pocp.com/blog/tag/digital-health-platforms)
- [eConsent (1)](https://blog.pocp.com/blog/tag/econsent)
- [eMedication Management (1)](https://blog.pocp.com/blog/tag/emedication-management)
- [healthcare (1)](https://blog.pocp.com/blog/tag/healthcare)
- [home health (1)](https://blog.pocp.com/blog/tag/home-health)
- [machine learning (1)](https://blog.pocp.com/blog/tag/machine-learning)
- [medical deserts (1)](https://blog.pocp.com/blog/tag/medical-deserts)
- [patient generated data (1)](https://blog.pocp.com/blog/tag/patient-generated-data)
- [payers (1)](https://blog.pocp.com/blog/tag/payers)
- [payment model (1)](https://blog.pocp.com/blog/tag/payment-model)
- [prescription drug monitoring programs (1)](https://blog.pocp.com/blog/tag/prescription-drug-monitoring-programs)
- [rural health (1)](https://blog.pocp.com/blog/tag/rural-health)
- [vive (1)](https://blog.pocp.com/blog/tag/vive)
See all
[](https://www.pocp.com)
©2026 Point-of-Care Partners | All Rights Reserved
- [](https://twitter.com/pocpHIT)
- [](http://www.linkedin.com/company/point-of-care-partners)
- [](https://www.pocp.com/pocp-blog/)
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "Tony Schueth",
"url" : "https://blog.pocp.com/blog/author/tony-schueth"
},
"dateModified" : "2020-06-19T15:25:55.375Z",
"datePublished" : "2018-10-04T15:53:19.000Z",
"headline" : "Opportunities to Improve Drug Price Transparency at the Point of Prescribing",
"image" : [ "https://blog.pocp.com/hubfs/Imported_Blog_Media/pa-web.jpg" ],
"mainEntityOfPage" : {
"@id" : "https://blog.pocp.com/blog/drug-price-transparency-blog",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.pocp.com/hubfs/pocp-logo-2016.jpg"
},
"name" : "Point-of-Care Partners"
}
}
```